Antivirals against the Chikungunya Virus
Copyright policy )Antivirals against the Chikungunya Virus
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that has re-emerged in recent decades, causing large-scale epidemics in many parts of the world. CHIKV infection leads to a febrile disease known as chikungunya fever (CHIKF), which is characterised by severe joint pain and myalgia. As many patients develop a painful chronic stage and neither antiviral drugs nor vaccines are available, the development of a potent CHIKV inhibiting drug is crucial for CHIKF treatment. A comprehensive summary of current antiviral research and development of small-molecule inhibitor against CHIKV is presented in this review. We highlight different approaches used for the identification of such compounds and further discuss the identification and application of promising viral and host targets.
- University of Vienna Austria
Antiviral drug development, SEMLIKI-FOREST-VIRUS, SELECTIVE INHIBITORS, in silico screening, In vivo validation, Review, Antiviral therapy, Direct-acting antivirals, Virus Replication, 301207 Pharmazeutische Chemie, Mice, INFECTION, antiviral therapy, alphavirus, CHLOROQUINE, DERIVATIVES, Chikungunya Fever/drug therapy, QR1-502, SDG 3 – Gesundheit und Wohlergehen, RIBAVIRIN, Chikungunya virus, 301207 Pharmaceutical chemistry, Alphavirus, Antiviral Agents/pharmacology, Microbiology, Antiviral Agents, medicine_pharmacology_other, In silico screening, SDG 3 - Good Health and Well-being, Drug Development, Host-directed antivirals, SURAMIN TREATMENT, Animals, Humans, Computer Simulation, Chikungunya virus/drug effects, direct-acting antivirals, Virus Replication/drug effects, Animal, host-directed antivirals, IN-VITRO, Disease Models, Animal, Culicidae, in vivo validation, REPLICATION, Disease Models, antiviral drug development, Chikungunya Fever, INTERFERON-ALPHA
Antiviral drug development, SEMLIKI-FOREST-VIRUS, SELECTIVE INHIBITORS, in silico screening, In vivo validation, Review, Antiviral therapy, Direct-acting antivirals, Virus Replication, 301207 Pharmazeutische Chemie, Mice, INFECTION, antiviral therapy, alphavirus, CHLOROQUINE, DERIVATIVES, Chikungunya Fever/drug therapy, QR1-502, SDG 3 – Gesundheit und Wohlergehen, RIBAVIRIN, Chikungunya virus, 301207 Pharmaceutical chemistry, Alphavirus, Antiviral Agents/pharmacology, Microbiology, Antiviral Agents, medicine_pharmacology_other, In silico screening, SDG 3 - Good Health and Well-being, Drug Development, Host-directed antivirals, SURAMIN TREATMENT, Animals, Humans, Computer Simulation, Chikungunya virus/drug effects, direct-acting antivirals, Virus Replication/drug effects, Animal, host-directed antivirals, IN-VITRO, Disease Models, Animal, Culicidae, in vivo validation, REPLICATION, Disease Models, antiviral drug development, Chikungunya Fever, INTERFERON-ALPHA
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).68 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!